Ever since the World Health Organization (WHO) declared COVID-19 a pandemic, biotech and pharmaceutical companies across the globe have been racing to develop both preventive and therapeutic interventions. While the entire Life Sciences industry is grappling to combat the situation, there are several industry and academia groups that are now turning to Artificial Intelligence (AI) tools for identification of more specified medicines and treatments that could help fight the pandemic.
AI has given a boost to the drug discovery process– along with identifying drug targets and finding the right molecules from data libraries, it also suggests chemical modifications and more importantly, enables drug repurposing. AI has been phenomenally used by many innovative companies to identify the biomarkers for various targets.
The situation of COVID-19 demands urgent and effective action. A number of medicines have been recognised as probable medicaments for the virus, but bringing these repurposed medications to the public for the current situation. This will require robust and high-quality clinical trials that could be brought about by the integration of AI in the drug development process.
Listen to this exclusive and discerning podcast by Dr. Anand Krishnamurthy, Senior Manager, Industry Process Consultant, BIOVIA, Dassault Systèmes to know how AI is changing and uplifting the Life Sciences industry, and how Dassault Systèmes with its long history in the drug development field, has fostered ingenious innovations that can change the drug discovery scenario of the world forever.
Enjoy the Podcast:
You can also listen to this podcast on: